Product Design, Manufacturing & Innovation Resources

Publicações recentes – Patentes em Imunologia e Vacinação

Imunologia Vacinologia

Dica: além da seleção abaixo, você pode pesquisar e filtrar nossos 2 bancos de dados completos:

> ferramenta de busca de publicações gratuitas < Por autor, tópico, palavras-chave, data ou periódico.

> ferramenta gratuita de busca de patentes < para patentes em inglês do Escritório Europeu de Patentes.

Immunology
Os avanços em imunologia e vacinologia impulsionam o desenvolvimento e a otimização de vacinas e sistemas de administração eficazes.

Immunology and vaccinology cover the mechanisms governing immune system function and the development of prophylactic and therapeutic vaccines. This domain integrates cellular and molecular immunology, antigen recognition, immune memory, and host-pathogen interactions to design and optimize vaccine formulations, adjuvants, and delivery systems. Research addresses immune modulation, immunopathology, and strategies to enhance vaccine efficacy against infectious diseases, cancers, and autoimmune disorders. Our continuously updated compilation presents the latest peer-reviewed studies and patented tecnologias advancing immunological understanding and vaccine innovation:

Esta é a nossa mais recente seleção de publicações e patentes mundiais em inglês sobre Imunologia e Vacinação, provenientes de diversos periódicos científicos online, classificadas e focadas em antígeno, anticorpo, célula T, célula B, imunógeno, epítopo, adjuvante, imunização, eficácia da vacina, resposta imune, célula de memória, citocina, imunoglobulina, anticorpo neutralizante, imunoterapia, receptor de reconhecimento de patógenos, complexo principal de histocompatibilidade, imunologia, vacina, tolerância imunológica, célula dendrítica, imunidade humoral, imunidade celular, formulação de vacinas, vacina viva atenuada, vacina de subunidade, imunidade da mucosa, memória imunológica, ponto de controle imunológico, adjuvante de vacina, imunopatologia e imunomodulação.

Novel methods for lyophilized kefir-loaded self-nanoemulsifying delivery system of caraway oil and licorice extract on cognitive function via the micr

Patent published on the 2026-07-02 in US under Ref US20260183352 by UNIV OF SHARJAH [AE] (Anwar Mai Mamdouh [eg], Amin Amr [ae], Boseila Amira A [eg])

Abstract: Chronic inflammatory bowel disorders (IBDs) are characterized by altered intestinal permeability, prompting inflammatory, oxidative stress and immunological factors. Gut microbiota disorders impact brain function via the bidirectional gut-brain axis, influencing behavior through inflammatory cascades, oxidative stress, and neurotransmitter levels. The present invention comprises lyophilized milk kefir alone and lyophilized milk kefir as solid carriers loaded with self-nanoemulsifying self-nanosu[...]


Our summary: The invention presents a lyophilized kefir-loaded delivery system for caraway oil and licorice extract aimed at improving cognitive function. Daily administration restores body weight, reduces inflammation, and normalizes neurotransmitter levels. It also improves gut microbiota and alleviates symptoms associated with inflammatory bowel disorders.

self-nanoemulsifying, lyophilized kefir, cognitive function, inflammatory bowel disorders

Patent

Vaccines against clostridioides difficile and methods of using the same

Patent published on the 2026-07-02 in WO under Ref WO2026143237 by CLOSTRIDIAL DISEASE PREVENTION INC [US] (Sasser Joseph [us])

Abstract: Disclosed are vaccine compositions comprising polypeptides selected from Closlridioides difficile binary toxin B, Closlridioides difficile binary toxin A, a High Molecular Weight portion of Closlridioides difficile Surface Layer Protein A, and a Low Molecular Weight portion of Closlridioides difficile Surface Layer Protein A. Methods of preparing the vaccine composition, methods of preventing or reducing attachment of C. difficile to an epithelial cell, and methods of preventing or treating a c[...]


Our summary: Vaccine compositions include polypeptides from C. difficile toxins and surface layer proteins. Methods for preparing the vaccine and preventing C. difficile attachment to epithelial cells are described. The vaccine aims to prevent or treat conditions caused by C. difficile infection.

vaccines, Clostridioides difficile, polypeptides, infection treatment

Patent

Canine recombinant allergen vaccine, preparation method therefor, and use thereof

Patent published on the 2026-07-02 in WO under Ref WO2026138849 by ZONHON BIOPHARMA INST INC [CN] (Zhao Baixue [cn], Gao Hui [cn], Zhuang Yu [cn], Ma Bruce Yong [cn], Wu Cheng [cn])

Abstract: Provided are a canine recombinant allergen vaccine, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof. The canine recombinant allergen vaccine is used for identifying, during diagnosis, an allergen molecule causing an allergic reaction, and is used for performing allergen immunotherapy on a patient during treatment.[...]


Our summary: The document describes a canine recombinant allergen vaccine and its preparation method. This vaccine is utilized for diagnosing allergen molecules responsible for allergic reactions. Additionally, it is employed in allergen immunotherapy for treatment purposes.

canine vaccine, recombinant allergen, immunotherapy, pharmaceutical composition

Patent

An engineered cell comprising a chimeric antigen receptor and a switchable chimeric antigen receptor, a kit and their use

Patent published on the 2026-07-02 in WO under Ref WO2026139826 by AVENCELL THERAPEUTICS INC [US] (Boyerinas Ben [us], Ashoura Norah [us], Spehr Johannes [de], Kuiper Emily [us])

Abstract: The present invention relates to an engineered cell comprising at least one chimeric antigen receptor (CAR) polypeptide and a switchable CAR in particular for use in the treatment of cancer, infectious disease or autoimmune disease, a pharmaceutical composition comprising the engineered cell and a kit comprising the engineered cell or at least two nucleic acids and/or vectors comprising a nucleotide sequence encoding the at least one CAR polypeptide or comprising a nucleotide sequence encoding t[...]


Our summary: This invention describes an engineered cell with a chimeric antigen receptor and a switchable chimeric antigen receptor. It is intended for the treatment of cancer, infectious diseases, or autoimmune diseases. The invention also includes a pharmaceutical composition and a kit containing the engineered cell or related nucleic acids and vectors.

chimeric antigen receptor, engineered cell, switchable CAR, pharmaceutical composition

Patent

Uses of antibody-drug conjugate in treating disease

Patent published on the 2026-07-02 in WO under Ref WO2026139913 by SHANGHAI HANSOH BIOMEDICAL CO LIMITED [CN] (Geng Yawen [cn], Zhang Huifeng [cn], Liu Qingyuan [cn], Huang Ying [cn], Pan Jianfeng [cn])

Abstract: This disclosure relates to the use of an antibody-drug conjugate for the treatment of head and neck cancer. Specifically, this disclosure provides a method for using an antibody-drug conjugate, a pharmaceutically acceptable salt, stereoisomer, or metabolite thereof, or a solvate of any of the foregoing, for the treatment of head and neck cancer, as well as a use of the antibody-drug conjugate in the preparation of a medicament for the prevention and/or treatment of head and neck cancer. The meth[...]


Our summary: This disclosure describes the use of an antibody-drug conjugate for treating head and neck cancer. It outlines a method for its application and the preparation of a medicament. The approach shows improved disease control and response rates.

antibody-drug conjugate, head and neck cancer, treatment method, disease control

Patent

Methods for responding to uplink trigger signal in mobile communications

Patent published on the 2026-07-02 in WO under Ref WO2026138573 by MEDIATEK INC [CN] (Tsai Chiou-wei [cn], Wu Wei-de [cn])

Abstract: Various solutions for responding to Uplink (UL) trigger signal with respect to an apparatus in mobile communications are described. The apparatus may receive a system information from a first cell. The system information may be associated with a second cell. The apparatus may receive a synchronization signal from the first cell. The apparatus may transmit a UL trigger signal to the second cell based on the system information and the synchronization signal. The apparatus may receive a response fr[...]


Our summary: This content discusses methods for responding to uplink trigger signals in mobile communications. It describes an apparatus that receives system information and synchronization signals from different cells. The apparatus transmits a UL trigger signal to a second cell and receives a response based on that signal.

Uplink trigger, mobile communications, synchronization signal, system information

Patent

pH-responsive amphiphilic peptide nanofibers facilitate endosomal escape for cytosolic protein delivery

Published on 2026-06-16 by Tomonori Waku, Chikae Sakata, Tomoki Matsuda, Kotone Minato, Hiroyasu Takemoto, Kazuya Matsuo, Akio Kobori @NATURE

Abstract: Polymer Journal, Published online: 16 June 2026; doi:10.1038/s41428-026-01212-2We developed pH-responsive amphiphilic peptide nanofibers (NFs) that may facilitate cytosolic protein delivery by selectively destabilizing endosomal membranes. The NFs were based on β-sheet-forming peptides conjugated with oligoglutamic acid segments, and the number of Glu residues was varied to optimize pH-responsive activity. Optimized NFs showed strong membrane-destabilizing activity at mildly acidic pH but remai[...]


Our summary: The study presents pH-responsive amphiphilic peptide nanofibers designed to enhance cytosolic protein delivery. These nanofibers destabilize endosomal membranes at mildly acidic pH while remaining stable at neutral pH. When tested with ovalbumin in dendritic cells, they improved MHC class I presentation of the OVA-derived epitope.

pH-responsive, amphiphilic, peptide nanofibers, cytosolic delivery

Publication

Surface-nanostructured cellulose gauze with terminally aminated low-molecular-weight cellulose for adsorbing bacteria

Published on 2026-06-15 by Yuuki Hata, Sayaka Okamoto, Yudai Mizuuchi, Hiroshi Tanaka, Takeshi Serizawa @NATURE

Abstract: Polymer Journal, Published online: 15 June 2026; doi:10.1038/s41428-026-01214-0We demonstrated the self-assembly of terminally aminated low-molecular-weight cellulose into nanostructures on gauze microfibers and the bacterial adhesion-promoting effects of the resulting nanostructured gauze across a wide range of protein concentrations. Terminally aminated low-molecular-weight cellulose formed either nanospike or nanofibrillar-network structures, depending on the solvent and coagulant used during[...]


Our summary: The study explores the self-assembly of terminally aminated low-molecular-weight cellulose into nanostructures on gauze microfibers. These nanostructures enhance bacterial adhesion through electrostatic interactions, even in protein-rich environments. Different solvent and coagulant conditions lead to varied nanostructure formations, influencing adhesion properties.

cellulose, nanostructures, bacterial adhesion, self-assembly

Publication

Tópicos abordados: Imunologia, Vacinação, Formulação de vacinas, Adjuvantes, Sistemas de administração, Modulação imunológica, Imunopatologia, Memória imunológica, Reconhecimento de antígenos, Interações hospedeiro-patógeno, Eficácia de vacinas, Doenças infecciosas, Vacinas terapêuticas, Vacinas profiláticas, Imunologia celular, Imunologia molecular, ISO 14155, ISO 13485, ISO 9001, ISO 17025 e ISO 14971.

Contexto histórico

1965
1970
1980
1980
1990
1960
1969
1976-05-28
1980
1990

(Caso a data seja desconhecida ou irrelevante, por exemplo, "mecânica dos fluidos", é fornecida uma estimativa aproximada de seu surgimento notável)

Imagens em tamanho real e downloads estão disponíveis apenas, 100% gratuitos, para membros registrados.